Fingerprint
Dive into the research topics of 'A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically